Jason Hassenstab on The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
COMMENT Donohue and colleagues have assembled a composite that shows excellent promise as a clinical trial endpoint. The composite is straightforward, easy to interpret, and strengthened by the theoretical and empirical bases underlying its construction. For ...